IL6 and congenital rubella syndrome: In preclinical CRS models, itacitinib (JAK1 inhibitor) significantly reduced the release of inflammatory cytokines, including interferon-γ (IFN-γ) and interleukin-6 (IL-6), IL-12, highlighting its potential in mitigating CRS (40).